PMV Pharma reports Q1 2022 net loss of $18.4M; cash at $294.8M; ASCO presentation on PC14586

PMV Pharmaceuticals, Inc.

2023-Q3 EPS reported -$0.41

Net loss of $18.4M for Q1 2022 vs $11.6M in Q1 2021; R&D spend increased to $11.8M.
Cash, equivalents and marketable securities totaled $294.8M as of March 31, 2022, down from $314.1M at year-end 2021.
Initial Phase 1/2 data for PC14586 (p53 Y220C reactivator) selected for oral presentation at ASCO 2022 on June 7.
Continued advancement of WIP1 inhibitor and p53 mutant pipeline programs.
Net cash used in operations was $18.0M in Q1 2022 vs $12.9M in Q1 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.